Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Dooms

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Bulletin - Cercle Benelux D'Histoire De La Pharmacie|July 4, 2015
[Medication: 15 years 'EU-directive orphan drugs']Marc Dooms
Intractable & Rare Diseases Research|March 31, 2017
From promising molecules to orphan drugs: Early clinical drug developmentMarc Dooms
Frontiers in Pharmacology|September 27, 2021
Orphan Drugs, Compounded Medication and Pharmaceutical CommonsKim Hendrickx, Marc Dooms
The International Journal of Risk & Safety in Medicine|September 9, 2017
Off-label use of medicines: The need for good practice guidelinesMarc Dooms, James Killick
Orphanet Journal of Rare Diseases|January 6, 2018
Compounded medication for patients with rare diseasesMarc Dooms, Maria Carvalho
Orphanet Journal of Rare Diseases|October 30, 2016
Off-label use of orphan medicinal products: a Belgian qualitative studyMarc Dooms, David Cassiman, Steven Simoens
Frontiers in Pharmacology|January 3, 2022
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)Annemieke Aartsma-Rus, Marc Dooms, Yann Le Cam
Applied Health Economics and Health Policy|June 21, 2011
Drugs for rare diseases: influence of orphan designation status on priceEline Picavet, Marc Dooms, David Cassiman, et al.
Drugs|July 4, 2012
Orphan drugs for rare diseases: is it time to revisit their special market access status?Steven Simoens, David Cassiman, Marc Dooms, et al.
Frontiers in Pharmacology|December 3, 2021
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in EuropeKhadidja Abdallah, Kris De Boeck, Marc Dooms, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Bulletin - Cercle Benelux D'Histoire De La Pharmacie|July 4, 2015
[Medication: 15 years 'EU-directive orphan drugs']Marc Dooms
Intractable & Rare Diseases Research|March 31, 2017
From promising molecules to orphan drugs: Early clinical drug developmentMarc Dooms
Frontiers in Pharmacology|September 27, 2021
Orphan Drugs, Compounded Medication and Pharmaceutical CommonsKim Hendrickx, Marc Dooms
The International Journal of Risk & Safety in Medicine|September 9, 2017
Off-label use of medicines: The need for good practice guidelinesMarc Dooms, James Killick
Orphanet Journal of Rare Diseases|January 6, 2018
Compounded medication for patients with rare diseasesMarc Dooms, Maria Carvalho
Orphanet Journal of Rare Diseases|October 30, 2016
Off-label use of orphan medicinal products: a Belgian qualitative studyMarc Dooms, David Cassiman, Steven Simoens
Frontiers in Pharmacology|January 3, 2022
Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group)Annemieke Aartsma-Rus, Marc Dooms, Yann Le Cam
Applied Health Economics and Health Policy|June 21, 2011
Drugs for rare diseases: influence of orphan designation status on priceEline Picavet, Marc Dooms, David Cassiman, et al.
Drugs|July 4, 2012
Orphan drugs for rare diseases: is it time to revisit their special market access status?Steven Simoens, David Cassiman, Marc Dooms, et al.
Frontiers in Pharmacology|December 3, 2021
A Comparative Analysis of Pricing and Reimbursement of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in EuropeKhadidja Abdallah, Kris De Boeck, Marc Dooms, et al.
Pageof 3